GMED icon

Globus Medical

83.93 USD
-0.20
0.24%
At close Feb 14, 4:00 PM EST
After hours
83.93
+0.00
0.00%
1 day
-0.24%
5 days
-4.58%
1 month
-4.82%
3 months
3.49%
6 months
25.12%
Year to date
2.57%
1 year
59.11%
5 years
48.44%
10 years
241.04%
 

About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.

Employees: 5,000

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $3.38M

2% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 53

1% less funds holding

Funds holding: 446 [Q2] → 442 (-4) [Q3]

2% less capital invested

Capital invested by funds: $7.95B [Q2] → $7.79B (-$162M) [Q3]

6.72% less ownership

Funds ownership: 103.1% [Q2] → 96.39% (-6.72%) [Q3]

17% less repeat investments, than reductions

Existing positions increased: 144 | Existing positions reduced: 174

18% less funds holding in top 10

Funds holding in top 10: 22 [Q2] → 18 (-4) [Q3]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$90
7%
upside
Avg. target
$98
17%
upside
High target
$115
37%
upside

7 analyst ratings

positive
71%
neutral
29%
negative
0%
Canaccord Genuity
William Plovanic
71% 1-year accuracy
35 / 49 met price target
20%upside
$101
Buy
Maintained
10 Jan 2025
B of A Securities
Craig Bijou
43% 1-year accuracy
3 / 7 met price target
16%upside
$97
Neutral
Upgraded
9 Jan 2025
Truist Securities
Richard Newitter
74% 1-year accuracy
31 / 42 met price target
7%upside
$90
Hold
Maintained
18 Dec 2024
Roth MKM
Jason Wittes
58% 1-year accuracy
11 / 19 met price target
37%upside
$115
Buy
Maintained
17 Dec 2024
BTIG
Ryan Zimmerman
68% 1-year accuracy
32 / 47 met price target
8%upside
$91
Buy
Maintained
12 Dec 2024

Financial journalist opinion

Based on 11 articles about GMED published over the past 30 days

Positive
Zacks Investment Research
3 days ago
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Positive
Zacks Investment Research
5 days ago
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
Neutral
Business Wire
6 days ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the.
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
Neutral
GlobeNewsWire
1 week ago
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Positive
Zacks Investment Research
1 week ago
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
Negative
Benzinga
1 week ago
Top 2 Health Care Stocks That May Crash In February
As of Feb. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 2 Health Care Stocks That May Crash In February
Neutral
GlobeNewsWire
2 weeks ago
Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
Positive
Zacks Investment Research
3 weeks ago
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
3 weeks ago
Globus Medical Surges 62.1% in a Year: What's Driving the Stock?
GMED's strong synergies from the NuVasive merger and robust performance in the musculoskeletal solutions space bode well for investors.
Globus Medical Surges 62.1% in a Year: What's Driving the Stock?
Positive
Zacks Investment Research
3 weeks ago
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
Charts implemented using Lightweight Charts™